Cipla has received approval from board of directors to transfer Generics Business Undertaking as a going concern on a slump sale basis to Cipla Pharma and Life Sciences (CPLS), a wholly owned subsidiary of the Company. Effective date for completion of transfer to CPLS would be end of business hours of December 31, 2023, or such other date mutually agreed between the parties. The consideration to be received from such sale will be Rs 350 crore. The Board of Directors of the company at its meeting held on November 06, 2023 have inter alia, approved the same.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: